Hamilton Lane Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Hamilton Lane Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-23,812	Closed	-$363K	–	60
2016 Q1	$363K	Sell	23,812 -122,089	-84%	-$1.59M	0.17%	46
2015 Q4	$1.96M	Buy	+145,901	New	+$2.26M	0.86%	26
2015 Q3	–	Sell	-18,806	Closed	-$319K	–	59
2015 Q2	$319K	Buy	+18,806	New	+$268K	0.12%	54

Other funds holding SUPN

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hamilton Lane Advisors's SUPN Position: Q2 2016 in Review

Hamilton Lane Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2016, closing a stake of 23,812 shares — an estimated $363K sold.

Hamilton Lane Advisors first reported a position in SUPN in Q2 2015 and held it in 3 quarters. The position peaked at $1.96M in Q4 2015. 214 funds tracked by Wall St. Rank hold SUPN as of Q2 2016.

Hamilton Lane Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Hamilton Lane Advisors sold 23,812 Supernus Pharmaceuticals shares in Q2 2016, an estimated $363K.
Hamilton Lane Advisors first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 3 quarters.
Hamilton Lane Advisors's Supernus Pharmaceuticals position peaked at $1.96M in Q4 2015.
214 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2016.

Based on Hamilton Lane Advisors's 13F filing for Q2 2016, filed 12 Jul 2016.